<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Carmustine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00262</strong>&#160; (APRD00006)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (<span class="caps">NTP</span> 85-002, 1985). (From Merck Index, 11th ed)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00262/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00262/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00262.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00262.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00262.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00262.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00262.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00262">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>BCNU</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>bis-chloroethylnitrosourea</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N,N'-Bis(2-chloroethyl)-N-nitrosourea</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Becenun</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>BiCNU</td><td>Bristol-Myers Squibb</td></tr><tr><td>Carmubris</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Carustine</td><td>Curacell Biotech</td></tr><tr><td>Gliadel</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gliadel Wafer</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nitrumon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents-alkylating">Antineoplastic Agents, Alkylating</a></li></ul></td></tr><tr><th>CAS number</th><td>154-93-8</td></tr><tr><th>Weight</th><td>Average: 214.05<br>Monoisotopic: 213.007181961</td></tr><tr><th>Chemical Formula</th><td>C<sub>5</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>DLGOEMSEDOSKAD-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1,3-bis(2-chloroethyl)-1-nitrosourea</div></td></tr><tr><th>SMILES</th><td><div class="wrap">ClCCNC(=O)N(CCCl)N=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organonitrogen Compounds</td></tr><tr><th>Class</th><td>Hydrazines and Derivatives</td></tr><tr><th>Subclass</th><td>Semicarbazides</td></tr><tr><th>Direct parent</th><td>Semicarbazides</td></tr><tr><th>Alternative parents</th><td>Polyamines; Organochlorides; Alkyl Chlorides</td></tr><tr><th>Substituents</th><td>polyamine; organochloride; amine; organohalogen; alkyl halide; alkyl chloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the semicarbazides. These are organic compounds containing the semicarbazide functional grou with the general structure R1(N)R2NR3C(=O)N(R4)R5 (R1-R5=H,alkyl,aryl), a derivative of urea, where the amine group on one side has been replace by an hydrazine group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.</td></tr><tr><th>Pharmacodynamics</th><td>Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.</td></tr><tr><th>Mechanism of action</th><td>Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.</td></tr><tr><th>Absorption</th><td>5 to 28% bioavailability</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>80%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic and rapid with active metabolites. Metabolites may persist in the plasma for several days.</p></td></tr><tr><th>Route of elimination</th><td>Approximately 60% to 70% of a total dose is excreted in the urine in 96 hours and about 10% as respiratory CO2.</td></tr><tr><th>Half life</th><td>15-30 minutes</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The oral LD<sub>50</sub>s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9533</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5621</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7552</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.797</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8778</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8177</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7656</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8491</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.672</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9031</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9131</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9577
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Carcinogens  
        </td>
        <td>
            0.688
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.5596
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.9975 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.7278
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.919
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Eisai inc</li>
<li>Bristol laboratories inc div bristol myers co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.eisai.com">Eisai Inc.</a></li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li>MGI Pharma</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr><tr><td>Wafer</td><td>Intralesional</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Increases myelosuppression caused by carmustine</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01097">Leflunomide</a></td><td>Immunosuppressants such as carmustine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. </td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The antineoplasic agent decreases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00337">Pimecrolimus</a></td><td>Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. </td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Echinacea</li></ul></td></tr></tbody></table>